+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H2 2020

  • PDF Icon

    Drug Pipelines

  • 70 Pages
  • September 2020
  • Region: Global
  • Global Markets Direct
  • ID: 5174777
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Lassa Fever - Pipeline Review, H2 2020, provides an overview of the Lassa Fever (Infectious Disease) pipeline landscape.

Lassa fever is an acute viral hemorrhagic illness caused by Lassa virus, a member of the arenavirus family of viruses. It is transmitted to humans from contacts with food or household items contaminated with rodent excreta. Symptoms include fever, headache, chills, back pain, weight loss, swollen neck, rashes and bleeding.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Lassa Fever - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Lassa Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Lassa Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Lassa Fever (Lassa Hemorrhagic Fever) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 3, 8 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

Lassa Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Lassa Fever (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Lassa Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Lassa Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Lassa Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Lassa Fever (Infectious Disease)

Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Lassa Fever (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Lassa Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Introduction
  • Report Coverage

Lassa Fever (Lassa Hemorrhagic Fever) - Overview
Lassa Fever (Lassa Hemorrhagic Fever) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes

Lassa Fever (Lassa Hemorrhagic Fever) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type

Lassa Fever (Lassa Hemorrhagic Fever) - Companies Involved in Therapeutics Development
  • Curevac AG
  • Emergent BioSolutions Inc
  • Etubics Corp
  • FUJIFILM Toyama Chemical Co Ltd
  • GeoVax Labs Inc
  • Globavir Biosciences Inc
  • Inovio Pharmaceuticals Inc
  • Kineta Inc
  • Medigen Inc
  • RetroVirox Inc
  • Themis Bioscience GmbH
  • Zalgen Labs LLC

Lassa Fever (Lassa Hemorrhagic Fever) - Drug Profiles
(Ebola + Lassa Fever + Marburg) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

(Lassa fever + rabies) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

arevirumab-3 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

favipiravir - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

GBV-006 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

GEOLM-01 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

hemorrhagic fever vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

INO-4500 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

lassa fever vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

lassa fever vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

lassa fever vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

lassa fever vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

lassa fever vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

Lassa fever vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

lassa vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

LHF-535 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

ML-29 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

Small Molecules for Lassa Fever - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

Lassa Fever (Lassa Hemorrhagic Fever) - Dormant Projects
Lassa Fever (Lassa Hemorrhagic Fever) - Product Development Milestones
  • Featured News & Press Releases
  • Oct 30, 2019: Themis Bioscience and CEPI trial Lassa fever vaccine
  • Aug 06, 2019: Kineta Secures $1.8 Million Funding Boost from Wellcome Trust on Positive Phase 1a Clinical Study Results with LHF-535
  • Jul 16, 2019: GeoVax announces upcoming presentation of lassa fever vaccine data
  • Jul 15, 2019: Kineta secures NIAID grant worth up to $5.8M to evaluate LHF-535 in Arenaviruses
  • May 23, 2019: Inovio doses patients in Phase I trial of Lassa virus vaccine INO-4500
  • Dec 11, 2018: Batavia Biosciences Partners with IAVI to Advance Development of Vaccine Against Lassa Fever
  • Sep 26, 2018: GeoVax awarded $2.4 million from U.S. Department of Defense to advance Lassa Fever Vaccine
  • Sep 15, 2018: Advanced preclinical development and production of master seed virus of GEO-LM01, a novel MVA-VLP vaccine against Lassa Fever
  • Sep 05, 2018: Kineta initiates first-in-human clinical trial of LHF-535 a novel therapy for lassa fever
  • Aug 20, 2018: Emergent and Profectus receive CEPI contract for Lassa virus vaccine
  • Jun 27, 2018: NIAID Scientists Recommend Favipiravir for Human Trials of Lassa Fever Virus
  • Apr 10, 2018: GeoVax Awarded NIH Fast Track Phase I/II Grant to Advance Lassa Fever Vaccine
  • Oct 24, 2017: Inovio and U.S. Army Co-developing Novel Vaccine That Completely Prevents Lethal Lassa Fever Infection in Pre-Clinical Study
  • Jul 24, 2017: GeoVax Joins with Scripps Research Institute and Institute of Human Virology at University of Maryland School of Medicine to Develop Lassa Fever Vaccine
  • Jul 11, 2017: Tulane University awarded $12 million to create Lassa vaccine and treatment

Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact
  • Disclaimer

List of Tables
  • Number of Products under Development for Lassa Fever (Lassa Hemorrhagic Fever), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Curevac AG, H2 2020
  • Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Emergent BioSolutions Inc, H2 2020
  • Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Etubics Corp, H2 2020
  • Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by FUJIFILM Toyama Chemical Co Ltd, H2 2020
  • Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by GeoVax Labs Inc, H2 2020
  • Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Globavir Biosciences Inc, H2 2020
  • Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Inovio Pharmaceuticals Inc, H2 2020
  • Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Kineta Inc, H2 2020
  • Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Medigen Inc, H2 2020
  • Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by RetroVirox Inc, H2 2020
  • Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Themis Bioscience GmbH, H2 2020
  • Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Zalgen Labs LLC, H2 2020
  • Lassa Fever (Lassa Hemorrhagic Fever) - Dormant Projects, H2 2020

List of Figures
  • Number of Products under Development for Lassa Fever (Lassa Hemorrhagic Fever), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Targets, H2 2020
  • Number of Products by Stage and Targets, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Curevac AG
  • Emergent BioSolutions Inc
  • Etubics Corp
  • FUJIFILM Toyama Chemical Co Ltd
  • GeoVax Labs Inc
  • Globavir Biosciences Inc
  • Inovio Pharmaceuticals Inc
  • Kineta Inc
  • Medigen Inc
  • RetroVirox Inc
  • Themis Bioscience GmbH
  • Zalgen Labs LLC